|
|
|
| Professor Zhou Yongming’s experience in differentiating and treating cancer-related anemia |
| WANG Kai LI Changgui ZHOU Yongming |
| Department of Hematology, Yueyang Hospital of Integrated Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China |
|
|
|
Abstract Summarize Professor Zhou Yongming’s clinical experience in the differentiation and treatment of cancer-related anemia (CRA). Professor Zhou believes that CRA belongs to the category of “consumptive disease”, “blood deficiency” and “loss of flourishing” in Chinese medicine. The pathology is characterized by asthenia in origin and asthenia in superficiality and intermingled deficiency and excess. It is argued that CRA roots from spleen and kidney deficiency, exhibits the internal accumulation of phlegm, dampness, blood stasis and toxin, and the change of internal invasion of fire-toxicity. The use of enforcing spleen and nourishing kidney, eliminating evil and detoxification can achieve good therapeutic effect. Professor Zhou suggests that CRA should be treated as early as possible, and the treatment should follow the principle of individualization in Chinese medicine, grasp the key point of eliminating pathogen and strengthening vital qi, and be flexible to take corresponding measures according to the different stages of chemotherapy.
|
|
|
|
|
|
[1] 林果为，王小钦.提高肿瘤相关性贫血的诊断和治疗水平[J].肿瘤，2008，28（9）：727-729.
[2] 陈莹，李银玲，周祖平，等.肿瘤相关性贫血原因[J].生命的化学，2021，41（8）：1747-1753.
[3] MacciòA，Madeddu C，Gramignano G，et al. The role of inflammation，iron，and nutritional status in cancer-related anemia：results of a large，prospective，observational study [J]. Haematologica，2015，100（1）：124-132.
[4] MacciòA，Madeddu C，Massa D，et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer：role of inflammation in cancer-related anemia [J]. Blood，2005，106（1）：362-367.
[5] Gilreath JA，Stenehjem DD，Rodgers GM. Diagnosis and treatment of cancer-related anemia [J]. Am J Hematol，2014，89（2）：203-212.
[6] Madeddu C，Gramignano G，Astara G，et al. Pathogenesis and treatment options of cancer related anemia：perspective for a targeted mechanism-based approach [J]. Front Physiol，2018，9：1294.
[7] Furrer R，Jauch AJ，Nageswara Rao T，et al. Remodeling of metabolism and inflammation by exercise ameliorates tumor-associated anemia [J]. Sci Adv，2021，7（37）：eabi4852.
[8] Weiss G，Ganz T，Goodnough LT. Anemia of inflammation [J]. Blood，2019，133（1）：40-50.
[9] 宋正波，陆舜，冯继锋，等.中国肿瘤相关性贫血发生率及治疗现状的流行病学调查研究[J].中国肿瘤，2019，28（9）：718-722.
[10] 侯丽，董青，田劭丹，等.肿瘤相关性贫血中医药防治专家共识[J].北京中医药，2021，40（1）：48-52.
[11] Natalucci V，Virgili E，Calcagnoli F，et al. Cancer related anemia：an integrated multitarget approach and lifestyle interventions [J]. Nutrients，2021，13（2）：482.
[12] Barca-Hernando M，Mu?觡oz-Martin AJ，Rios-Herranz E，et al. Case-control analysis of the impact of anemia on quality of life in patients with cancer：a qca study analysis [J]. Cancers（Basel），2021，13（11）：2517.
[13] Lloyd A，van Hanswijck de Jonge P，Doyle S，et al. Health state utility scores for cancer-related anemia through societal and patient valuations [J]. Value Health，2008，11（7）：1178-1185.
[14] Steinmetz T，Totzke U，Schweigert M，et al. A prospective observational study of anaemia management in cancer patients-results from the German Cancer Anaemia Registry [J]. Eur J Cancer Care（Engl），2011，20（4）：493-502.
[15] 马军，王杰军，张力，等.肿瘤相关性贫血临床实践指南（2015—2016版）[J].中国实用内科杂志，2015，35（11）：921-930.
[16] 徐漫漫，姚书忠.从妇科角度解读《肿瘤相关性贫血临床实践指南》（2015～2016版）[J].实用妇产科杂志，2018， 34（3）：179-182.
[17] Ludwig H，Van Belle S，Barrett-Lee P，et al. The European Cancer Anaemia Survey（ECAS）：a large，multinational，prospective survey defining the prevalence，incidence，and treatment of anaemia in cancer patients [J]. Eur J Cancer，2004，40（15）：2293-2306.
[18] Madeddu C，Neri M，Sanna E，et al. Experimental drugs for chemotherapy- and cancer-related anemia [J]. J Exp Pharmacol，2021，13：593-611.
[19] 路艳，徐志伟，张进，等.从“肾藏精，生髓，化血”理论谈血液的化生[J].时珍国医国药，2012，23（9）：2297-2298.
[20] 温昊天，隋华，李琦，等.干细胞与中医理论关系的思考[J].中华中医药杂志，2017，32（4）：1422-1424.
[21] 郑在根，郑洪新.肾主血的理论探讨[J].中华中医药杂志，2014，29（11）：3553-3554.
[22] 朱嘉欢，黄小平，邓常清.黄芪和当归的主要活性成分配伍促进衰老造血干细胞增殖作用的研究[J].中草药，2019，50（1）：111-119.
[23] 刘涓，张弛，吴爱明，等.补肾生血解毒方对再生障碍性贫血小鼠造血干细胞增殖的影响[J].北京中医药大学学报，2013，36（8）：538-541.
[24] 徐尚福，潘丽，袁毅，等.人参皂苷Rg1对CD133+和CD34+脐血造血干细胞增殖分化的影响[J].中华中医药学刊，2020，38（11）：37-40，260-262.
[25] 王岩航，叶效明，姚璐，等.淫羊藿苷元治疗血小板减少症的靶点鉴定及作用机制研究[J].中草药，2021，52（17）：5250-5257. |
|
|
|
